Profile of infective endocarditis observed from 2003 - 2010 in a single center in Italy by L. Ferraris et al.
Ferraris et al. BMC Infectious Diseases 2013, 13:545
http://www.biomedcentral.com/1471-2334/13/545RESEARCH ARTICLE Open AccessProfile of infective endocarditis observed from
2003 - 2010 in a single center in Italy
Laurenzia Ferraris1,2*, Laura Milazzo1,2, Davide Ricaboni1,2, Cristina Mazzali1, Giovanna Orlando3, Giuliano Rizzardini4,
Marco Cicardi1,5, Ferdinando Raimondi6, Loredana Tocalli7, Alessandro Cialfi8, Paolo Vanelli9, Massimo Galli1,2,
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Background: This study aimed to provide a contemporary picture of the epidemiologic, clinical, microbiologic
characteristics and in-hospital outcome of infective endocarditis (IE) observed in a single center in Italy.
Methods: We performed a retrospective study of patients with definite or probable IE observed at the “L. Sacco”
Hospital in Milan, Italy, from January 1, 2003 through December 31, 2010.
Results: 189 episodes of IE in 166 patients were included. The mean number of incident IE in the study period was
of 1.27 (range 0.59-1.76) cases per 1000 patients admitted. The median age of the cohort was 57 (interquartile
range, 43-72) years, 63% were male and 62.5% had native valve IE. Twenty-six percent were active intravenous drug
users (IVDU), 29% had a health care-associated IE and 5% chronic rheumatic disease. Twenty-nine percent of the
cases occurred in patients affected by chronic liver disease and 19% in HIV positive subjects. Staphylococcus aureus
was the most common pathogen (30%), followed by streptococci. The mitral (34%) and aortic (31%) valves were
involved most frequently. The following complications were common: stroke (19%), non-stroke embolizations (25%),
heart failure (26%) and intracardiac abscess (9%). Surgical treatment was frequently employed (52%) but in hospital
mortality remained high (17%). Health care-associated IE and complications were independently associated with an
increased risk of in-hospital death, while surgery was associated with decreased mortality.
Conclusion: S. aureus emerged as the leading causative organism of IE in a University hospital in northern Italy. Our
study confirmed the high in-hospital mortality of IE, particularly if health care associated, and the protective role
of surgery.
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SurgeryBackground
The incidence of infective endocarditis (IE) has not de-
creased over the past 30 years, affecting between 2 and 6
per 100,000 subjects per year; however, in recent years,
the epidemiology and clinical characteristics of IE have
changed meaningfully [1-6]. Despite advances in medical
and surgical therapy the associated mortality has remained
between 10 and 30%, depending on the causative micro-
organism, the underlying conditions, and whether the* Correspondence: laurenzia.ferraris@unimi.it
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reproduction in any medium, provided the orinfection occurred on native or prosthetic heart valve
[7,8]. The emerging population at risk for IE consists of
patients with health care-associated infections (acquired
during hospitalization or following invasive procedures,
mainly haemodialysis and chronic intravenous [IV] cathe-
ters), elderly people with degenerative valvulopathy, pa-
tients with prosthetic valves or intracardiac devices
[2,6,9,10]. Other coexisting risk factors are diabetes melli-
tus and intravenous drug use [2,4,6,9-11]. The expansion
of the elderly population with degenerative valve disease
as well as the rise in staphylococcal infections suggest that
IE will remain a significant health problem in the near fu-
ture [12]. Oral streptococci are the predominant causative
pathogen of IE in the general population [3,4,13], whereasLtd. This is an open access article distributed under the terms of the Creative
ommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and
iginal work is properly cited.
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cocci (mainly S. epidermidis) are more often found in
IVDU, in patients with prosthetic-valve endocarditis (PVE)
or health care-associated IE [2,14-16]; furthermore group
D streptococci (mainly S. bovis) are increasingly prevalent
in elderly patients and are often associated with colon can-
cer [2-4,17,18]. The aim of this study was to describe a
single-center cohort of patients with IE admitted in a ter-
tiary care hospital in Milano, Italy, with particular em-
phasis on the clinical presentation, microbial aetiology,
treatment and in-hospital mortality.
Methods
Design, patients and settings
A retrospective review of consecutive cases of IE was
conducted at Luigi Sacco Hospital, a 550-bed university
hospital, that is a referral center for infectious diseases
(three wards) and cardiac surgery in the metropolitan
area of Milano, Italy. The study was approved by the
hospital Institutional Review Board (Comitato Etico per
la sperimentazione clinica, Azienda Ospedaliera-Polo
Universitario Luigi Sacco) and was conducted in accord-
ance with the Declaration of Helsinki. All records from
the years 2003–2010 were searched in the in-hospital
database using discharge diagnosis according to the
International Classification of Diseases, Ninth Revision
(ICD-9) codes. Eighteen out of 207 records retrieved
were excluded from the analysis: 4 patients did not have
either definite or possible IE by Duke criteria, 14 pa-
tients had incomplete data or their clinical charts were
unavailable. Of the remaining cases, 189 episodes occur-
ring in 166 patients were evaluated.
IE was defined as definite or possible according to the
modified Duke criteria [19]. Demographic data, clinical
manifestations, treatment and in-hospital outcome infor-
mation, laboratory and microbiology findings, were re-
corded into an electronic database. All clinical samples
were collected as part of standard patient care.
Echocardiographic data and case classification
Echocardiographic findings, inclusive of exam modality
(transthoracic or transoesophageal), presence, size, loca-
tion and mobility of vegetations; presence of valvular
insufficiency; inferior vena cava size and caliber were re-
corded. Vital signs and pulmonary artery pressure were
reported if available. Cases were also classified based on
the valve involvement (tricuspid, mitral, aortic or pul-
monary), whether native (NVE) or prosthetic (PVE)
and according to the side (right, left or bilateral) of
endocarditis. PVE were further defined as early and late
recurrences, based on the timing of infection: within one
year of the valve replacement or afterwards, respectively
[20]. Infection of mitralic valvuloplasty and cardiac im-
plantable electronic device-related IE (CIED-IE) thatincluded pacemaker (PM) and implantable cardioverter
defibrillator (ICD) infections, were integrated in the PVE
group.
Health care-associated IE has been defined elsewhere
[9-11]. Episodes of IE recurring more than 6 months
after the end of therapy or within the 6 months period
after therapy but caused by a different microorganism
were considered reinfections; when IE was caused by the
same microorganism within the 6 months period after
the initial episode it was classified as a relapse.
Statystical analysis
Categorical variables were expressed as number of cases
(percentage); continuous variables were expressed as
median ± interquartile range. Continuous data were ana-
lyzed using Wilcoxon non-parametric test, whereas for
categorical variables Chi-square or Fisher exact tests
were used for the analysis. Tests were two-sided and a
p value less than 0.05 was considered statistically signifi-
cant. Distribution of sex and age was evaluated on inci-
dent cases.
Incidence of endocarditis was calculated considering all
hospitalized patients at L. Sacco Hospital from 2003 to
2010, and Chocran-Armitage trend test was performed.
Multiple linear regression analysis was performed to
identify independent predictors of in-hospital mortality.
A generalized linear model for binary response was used,
and the presence of repeated measures for the same
subject was handled through generalized estimating
equations (GEE) method. An autoregressive model of
covariances was considered. Age, sex and those vari-
ables, which presented a p-value less than 0.20 in univar-
iate analyses, were entered in the final model. Analyses
were performed using SAS® 9.2 (SAS Institute, Cary, NC,
USA); GENMOD procedure was used for univariate and
multivariate analyses.
Results
A total of 189 episodes of IE were identified during the
study period in 166 patients (104 males, 62 females).
Baseline characteristics are shown in Table 1. The ma-
jority of cases (67%) were initially admitted to the Infec-
tious Diseases Department; 27 (14%) to the Cardiac
Surgery and cardiological-intensive care unit (ICU), 16
(9%) to the Internal Medicine wards, 7 (4%) to the gen-
eral ICU, 6 (3%) to Cardiology ward and the remainder
6 (3%) to other wards.
After excluding prevalent cases, the mean number
of incident IE over the period 2003–2010 at Luigi
Sacco Hospital was 1.27 (range: 0.59-1.76) cases per
1000 admissions, without a statistically significant
trend (p = 0.0671) (Figure 1). One hundred and forty-
four cases (76%) were diagnosed as definite IE and the
remainder as probable IE.
Table 1 General characteristics of 166 patients with infective endocarditis (IE)
No. (%) of patients
pCharacteristic TOTAL Native valve Prosthetic valve
(189 events, 166 patients) (118 events, 111 patients) (71 events, 55 patients)
Age (years), median [IQR] 57 [43–72] 53 [42–71] 66 [50–75] 0.01
Male gender 104 (63%) 72 (65%) 32 (58%) 0.4
Time from onset of symptoms to admission
< 7 days 69 (37%) 41 (35%) 28 (39%)
>7 and ≤21 days 42 (22%) 25 (21%) 17 (24%)
> 21 days 55 (29%) 34 (29%) 21 (30%) 1
NA 23 (12%) 18 (15%) 5 (7%)
Co-morbidities
Cancer 14 (7%) 13 (11%) 1 (1%) 0.01
Hypertension 39 (21%) 21 (18%) 18 (25%) 0.2
Acute/chronic renal failure 17 (9%) 6 (5%) 11 (15%) 0.02
Ischemic cardiopathy 21 (11%) 9 (8%) 12 (17%) 0.05
Diabetes mellitus 29 (15%) 17 (14%) 12 (17%) 0.6
COPD 9 (5%) 4 (3%) 5 (7%) 0.2
CLD 55 (29%) 41 (35%) 14 (20%) 0.03
HIV infection 35 (19%) 27 (23%) 8 (11%) 0.05
CD4 cells/μL [IQR] 268 [145–353] 248 [124–313] 447 [348–1814] 0.008
HIV-RNA cp/mL (n 22)
<10000 14 (40%) 8 (30%) 6 (75%)
10000-100000 5 (14%) 4 (15%) 1 (13%) 0.11
>100000 4 (11%) 4 (15%) 0
NA 12 (34%) 11 (41%) 1 (13%)
HAART at IE
No 21 (60%) 15 (56%) 6 (75%) 0.2
Yes 14 (40%) 12 (44%) 2 (25%)
Data are median [interquartile range] or numbers (%).
NA, Not available; COPD, Chronic obstructive pulmonary disease; CLD, Chronic liver disease; HAART, Highly active antiretroviral therapy.
Figure 1 Incident cases of IE observed at the L. Sacco Hospital in the period 2003–2010: p = 0.067 according to Cochran-Armitage
trend test.
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Underlying disorders and predisposing conditions are
summarized in Tables 1 and 2. Seventy-one percent of
IE were classified as community acquired, 29% as health
care-associated. Left-sided IE occurred in 140 cases
(74%), right-sided IE in 44 (23%) cases; 5 episodes (3%)
involved both heart sides. Seventy-one events interested
prosthetic valves (72% biologic valves). Aortic valve was
affected in 65 cases (34%), mitral valve in 59 cases (31%),
tricuspid valve in 38 cases (20%). Multiple valve involve-
ment was more commonly observed in native rather
than prosthetic valves (21/118 cases [18%] vs 3/71 cases
[4%], respectively; p = 0.007).
Fever was the main sign of clinical presentation ob-
served in 81% of cases and a new onset or a worsening
cardiac murmur was reported in 79% of cases. Notably,
29% of patients diagnosed to have IE in our cohort had
been admitted after a long history of fever (>21 days).
The mean WBC count on admission was 9670 cells/μL
(IQR: 7190–12910 cells/μL), haemoglobin was 10.5 g/dL
(IQR: 9.2-12.1 g/dL), creatinine 0.9 mg/dL (IQR: 0.7-
1.48 mg/dL), lactic dehydrogenase (LDH) 345 U/L (IQR:
244.5-474.5 U/L) and C reactive protein (PCR) 54.7 mg/dL
(IQR: 9.75-146.75 mg/dL). No difference in laboratory
findings were found between NVE and PVE, except for
creatinine (0.84 [IQR: 0.7-1.2] mg/dL and 1.07 [IQR: 0.8-
1.83] mg/dL, respectively, p = 0.02), LDH (340 [IQR: 219–
449] U/L and 358 [IQR: 259–537] U/L, respectively, p =
0.04) and PCR (23.9 [IQR: 7.6-106] mg/dL vs 67 [IQR:
33.1-179] mg/dL, respectively, p = 0.003).
Relapses and reinfections
Throughout the study period 15 patients presented 23
recurrences (17 reinfections and 6 relapses). Twelve re-
currences out of 23 occurred in 7 active intravenous
drug users (IVDU), 5 of whom were HIV positive, and 3
were classified as relapses, whereas 9 as reinfections. In
6/15 patients recurrence occurred in native valves, whileTable 2 Underlying disorders and predisposing conditions in
No
TOTAL Nat
Current IV drug use 50 (26%) 3
Steroid therapy 5 (3%)
Previous IE 36 (19%) 1
Health care associated IE* 54 (29%) 3
Congenital heart disease 6 (3%)
Rheumatic heart disease 9 (5%)
Pacemaker 11 (6%)
Data are median [interquartile range] or numbers (%).
*Health care associated IE: chronic IV access/hemodialysis: 7/189 (4%); invasive proc
(4%) hospitalized in an acute care hospital before IE 38/189 (20%); resident in a nurin 9/15 a prosthetic valve was involved. All the recur-
rences affected the same valve of the first IE episode:
tricuspid (45%) and aortic (33%) disease prevailed, followed
by mitral involvement (22%). A different microorgan-
ism was isolated at any reinfection in 87% of cases:
staphylococci were the most common causative pathogens
(44%), followed by enterococci (26%), by streptococci
(22%) and by Gram negative bacteria (Pseudomans spp:
8%). The median time from the first episode of IE to the
recurrence was 1 year.
Echocardiographic findings
Echocardiographic description was available in 92% of
episodes, as 8% of subjects were referred to our center
with a diagnosis performed in other institutes. Sixty-
seven percent of patients underwent both transthoracic
(TTE) and transoesophageal (TEE) echocardiography.
Ninety-one percent of cases (158) had echocardio-
graphic evidence of vegetation, with significant valvular
regurgitation observed in 65% (113). The destruction of
valvular tissue was evidenced in 25% of cases (44), 70%
of which (31/44) were observed in NVE (fistula/perfor-
ation/rupture), with a prevalence of 28%, while 30%
(13/44) occurred in PVE, with a prevalence of dehis-
cence/paravalvular leakage in the latter group of 20%.
Moderate to severe regurgitation was more frequently
detected in NVE (84/111 cases [76%] vs 28/65 cases
[43%]; p = 0.0001).
Microbiology
Blood cultures were performed in 186 of the 189 epi-
sodes (98%). Of the 37 patients (20%) with negative
blood cultures, 24 (65%) had received antibiotics before
blood collection. Staphylococcus aureus was the most
frequently isolated pathogen in our series (44/149 epi-
sodes of IE, 30%); 16% of those strains were methicillin-
resistant Staphylococcus aureus (MRSA). Streptococcus
spp. was the second most prevalent organism (19%)patients with infective endocarditis (IE)
. (%) of patients
ive valve Prosthetic valve p
5 (30%) 15 (21%) 0.2
3 (3%) 2 (3%) 1
2 (10%) 24 (34%) <0.0001
3 (28%) 21 (30%) 0.3
6 (5%) 0 0.09
8 (7%) 1 (1%) 0.2
2 (2%) 9 (13%) 0.003
edures before IE (dental, urological and gastrointestinal procedures): 7/189
sing home or in a long-term care facility 2/189 (1%).
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streptococci 33.3%), followed by coagulase-negative staphylo-
cocci (CoNS 12%). No noticeable change was observed in ei-
ther distribution or antibiotic sensitivity of organisms during
the study period (data not shown). Microbial aetiology by
type of IE is reported in Figure 2.
No association between staphylococcal aetiology and
health care-associated IE was found (p = 0.6; data not
shown), whereas IE due to methicillin-resistant staphi-
lococci were significantly more likely to occur in PVE
patients than in NVE (p = 0.045). In addition, Staphylo-
coccus aureus was significantly more frequently isolated
in right-sided than in left-sided IE (18/44 cases, 41% vs
17/140 cases, 18% respectively; p < 0.0001) and in
IVDU compared to non-IVDU (19/50 cases, 38% vs 18/
136 cases, 13% respectively; p = 0.0002), while strepto-
coccal strains were more responsible for left-sided than
right-sided IE (32/140 cases, 23% vs 3/44 cases, 7% re-
spectively; p = 0.02) and for non-IVDU- compared to
IVDU-associated cases (31/136 cases, 23% vs 5/50
cases, 10% respectively; p = 0.05). We found that En-
terococcus spp. were significantly associated with left-
sided IE (p = 0.05) and CoNS infections were more
likely to occur in early recurrence of IE rather than in
late recurrence (7/24 cases, 29% vs 2/37 cases, 5% re-
spectively; p = 0.02).Figure 2 Microorganisms cultured according to the different type of
negative Staphylococci; Methicillin-resistant staphilococci: MRSA (methicillin
epidermidis. Streptococcus spp. includes: Viridans group Streptococci (overalCharacteristics of IE in the HIV-positive population
Thirty-five episodes of IE occurred in 27 HIV-infected
patients: most of them were male (81%) with a median
age of 42 (IQR 37–47) years and the major route of
HIV transmission was intravenous drug use (23; 85%).
Virological and immunological characteristics as well
as antiretroviral regimens at the time of IE are summa-
rized in Table 1. Compared with the HIV-negative
group, the HIV-infected patients had a higher incidence
of right-sided IE (48% vs 17%, p = 0.0001) and MSSA-
sustained infections (34% vs 17%, p = 0.02), mirroring
the higher prevalence of IVDU (85% vs 10% in HIV-
negative, p = 0.0001).
Complications, treatment and outcomes
Complications, treatment choice and in-hospital out-
come by type of IE are shown in Table 3. All patients
were treated with antibiotics for 4 to 6 weeks. The asso-
ciation of three or more antibiotics was observed more
frequently in PVE than NVE (p = 0.02). Overall, 99 pa-
tients (52%) underwent surgery, which was performed
on an elective basis in most patients (84%). The median
time between hospital admission and surgery was 22 days
(IQR 12–38).
In-hospital mortality was 17% (32 of 189 cases). Causes
of in-hospital death were septic shock with multiorganIE. MSSA: Methicillin-sensitive Staphylococcus aureus; CoNS: Coagulase-
-resistant Staphylococcus aureus), methicillin-resistant Staphylococcus
l 41.7%); S. bovis (overall 25%); other Streptococci (overall 33.3%).
Table 3 Complications, treatment and outcome of IE episodes
No. (%)
Characteristic TOTAL Native valve Prosthetic valve p
(189 cases) (118 cases) (71 cases)
Complications
Embolizations* 83 (44%) 56 (47%) 27 (38%) 0.4
Heart failure 49 (26%) 32 (27%) 17 (24%) 0.6
Arrhythmias 40 (21%) 28 (24%) 12 (17%) 0.3
Intracardiac abscess 15 (9%) 6 (5%) 9 (15%) 0.04
Renal failure 12 (6%) 6 (5%) 6 (8%) 0.4
Septic shock 8 (4%) 2 (2%) 6 (8%) 0.05
Medical treatment
Monotherapy 18 (10%) 13 (11%) 5 (7%)
0.02Dual therapy 115 (62%) 78 (68%) 37 (53%)
≥three drug therapy 52 (28%) 24 (21%) 28 (40%)
Surgical treatment
Medical and surgical 99 (52%) 65 (55%) 34 (47%) 0.3
Multiple valve procedures 24 (24%) 18 (15%) 6 (8%) 0.2
Surgical treatment timing
Emergency (≤48 h) 4 (4%) 3 (5%) 1 (3%)
0.4Urgent (>48 h and ≤7 days) 12 (12%) 9 (14%) 3 (9%)
Elective (> 7 days) 83 (84%) 53 (81%) 30 (88%)
In-hospital mortality 32 (17%) 16 (14%) 16 (23%) 0.1
Pre-operative 20 (63%) 11 (69%) 9 (56%)
0.8Intra-operative 2 (6%) 1 (6%) 1 (6%)
Post-operative 10 (31%) 4 (25%) 6 (38%)
*Embolizations: Stroke (35, 19%); Non-Stroke (48, 25%) [Pulmonary (21), Cutaneous (5); Upper/lower extremities (3); Myocardial infarction (1); Splenic (12); Bone (6)].
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32, 13%), surgery-related complications (8/32, 25%), such
as hemorrhagic shock, arrhythmias, metabolic acidosis
and systemic embolism. We did not find any statistically
significant difference between early (within 7 days) and
elective surgery regarding in-hospital mortality (p = 0.3;
data not shown).
Table 4 shows the results of the regression modeling
for in-hospital mortality. Among all the variables associ-
ated with increased mortality at univariate model, only
health care-associated IE (OR = 3.35, p = 0.01) and the
onset of any complication (OR = 5.58, p = 0.003) were
found to be independently associated with an increased
risk of in-hospital death in the multivariate analysis,
while surgery was independently associated with higher
in-hospital survival (OR 0.38, p = 0.04).
Discussion
Our study has several limitations and potential biases,
being retrospective and performed in a single referral
center with the largest Department of Infectious Diseasesin the city of Milano. Therefore, as for most of institu-
tional surveys, it cannot provide a representative picture
of IE incidence in the general population. Indeed, about
67% of all cases were hospitalized into the Infectious
Diseases Department, a figure that is lower in compari-
son with the 90% observed in a Japanese study [21]. It is
notable that in our series about 30% of all patients had a
long duration of symptoms (more than 3 weeks) before
hospital admission and, more notable, without any differ-
ence between those with NVE in comparison with PVE.
Since the majority of cases were admitted to investigate a
long-lasting fever, we can speculate that there is a low
awareness of the disease among general practitioners
even in the high risk population.
The incidence of IE in our cohort was of 1.27/1000 ad-
missions without a significant increase from 2003 to
2010. The median age (57 years), gender (63% males)
and prevalence of definite IE were in agreement with
data reported from recent reports [3,6,21]. Moreover,
consistently with recent studies conducted in Western
countries [9,18,22], about 30% of all episodes of IE in
Table 4 Results of multivariable regression modeling of
associations with in-hospital death
VARIABLE AOR (95% CI) p value
Age in 10 y intervals 1.26 (0.95-1.69) 0.1
Female sex 0.60 (0.20-1.78) 0.4
PVE early recurrence 0.88 (0.30-2.59) 0.8
PVE late recurrence 2.12 (0.80-5.58) 0.1
Intravenous drug use 0.60 (0.14-2.57) 0.5
Health care associated IE 3.35 (1.27-8.78) 0.01
CoNS – associated IE 0.50 (0.09-2.78) 0.4
Staphylococcus aureus 3.83 (0.95-15.44) 0.058
Viridans group streptococci 1.26 (0.33-4.77) 0.7
Others* 1.98 (0.58-6.80) 0.3
Mitral valve involvement 1.33 (0.53-3.30) 0.5
Complications** 5.58 (1.79-17.31) 0.003
Surgery 0.38 (0.16-0.94) 0.04
CoNS, Coagulase-negative staphilococci; MSSA, Methicillin-sensitive
Staphylococcus aureus; MRSA, Methicillin-resistant Staphylococcus aureus;
PVE, prosthetic valve endocarditis.
*Others: Enterococcus spp, Fungi/Yeast, Gram-negative bacteria, polymicrobial.
**Complications: heart failure, renal failure, stroke, non stroke embolization,
intracardiac abscess, septic shock, arrhythmias.
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probably reflecting the improved longevity with a con-
comitant increase of comorbidities, degenerative valvular
alterations and health care-associated infections. It is
worth noting that HIV infection was recorded in 19% of
episodes of IE in our series. This is a quite higher preva-
lence in comparison with a recent multicenter Italian
study [23] and a single center study from Spain [24].
Since in our hospital more than 6000 HIV-positive pa-
tients are regularly followed as outpatients, the high
prevalence of concomitant HIV infection is not unex-
pected among patients with a diagnosis of IE [25].
HIV-positive patients were younger (p = 0.0001), more
frequently male (p = 0.03), had higher frequency of
right-sided IE (p = 0.0001) and S. aureus was more
commonly identified in comparison with HIV-negative
subjects. All these aspects reflect the main risk factor
of acquisition of both HIV and IE in our population,
that is intravenous drug use.
Excluding HIV infection, chronic liver disease (CLD),
diabetes, and hypertension were the most commonly ob-
served comorbidities in our cohort. About one third of
our patients had CLD with a statistically significant dif-
ference among patients with NVE in comparison with
those affected by PVE (p = 0.03). Both CLD and diabetes
have been previously reported as important comorbidi-
ties and as independent predictors of mortality [26,27].
At variance with the above cited studies, in our analysis
neither CLD nor diabetes were found to be associated
with in-hospital mortality.Our study confirms recent data on the leading role of
S. aureus as the causative organism of IE either in Italy
and France [22,23]. The reported worldwide increase in
the incidence of IE due to S. aureus has been associated
with the widespread use of medical devices and proce-
dures that is also responsible of health care-associated
IE. However, in our experience it can be at least partly
attributed to an overrepresentation of IVDU, who carry
a high risk of percutaneous S. aureus exposure. Simi-
larly, the high incidence of recurrences observed in our
cohort (12% of cases), with 52% occurring in IVDU is
consistent with the high prevalence of IVDU among
our patients. Moreover, it cannot be ruled out that the
three cases defined as relapses in IVDU might have ac-
tually been a reinfection resulting from an ongoing ex-
posure to drugs injections.
Two disappointing findings of our study were the fact
that 2% of patients did not have blood cultures performed
and the high incidence of negative blood cultures (20%).
The first issue is essentially a cultural problem that needs
to be addressed by educational programs. The high pro-
portion of blood culture negative IE might be explained in
part by the fact that 64% of these patients had received an-
tibiotics by the time of blood sample taking. The propor-
tion of negative blood cultures ranged from 5 to 10% in
recent surveys from multicenter cohorts [3,6,23] that in-
volved selected tertiary care institutions. However, in the
Euro Heart Survey, a prospective study involving 92 cen-
ters from 25 European countries and in an Italian
population-based surveillance, the incidence of negative
blood cultures was 14% and 19.3%, respectively [26,28].
We believe that the microbiology diagnosis can be im-
proved by implementing either serological testing or mo-
lecular methods in order to detect rare and fastidious
bacteria and fungi that are difficult to grow [24,29-31]. In
agreement with other studies, heart failure and non-stroke
embolism were the most common clinical complications
observed in our experience [21,23,24]. As expected, intra-
cardiac abscess and septic shock were more frequently ob-
served among patients with PVE [32,33]. In our cohort
complications and health care-associated IE were the only
independent variables associated with in-hospital mortality
in a multivariable model.
Finally, in-hospital mortality in our cohort was 17%
that is similar to the death-rate reported in France, in
the Italian Study on Endocarditis and in a European sur-
vey and ranging from 12.6% to 16.6% [3,23,34]. In agree-
ment with a recent prospective analysis of the Italian
Study on Endocarditis, we found that surgery had a pro-
tective effect with respect to in-hospital mortality [23].
Conclusions
In conclusion, despite the availability of new and potent
antibiotics, modern echocardiography, and advanced
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mortality. This study provides a comprehensive, single-
center picture of IE, and, therefore, despite its limita-
tions, may allow to identify critical issues related to this
disease and possibly contributes to the improvement of
the clinical management of IE in our hospital.
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